WHO Advises Against Using Fluvoxamine and Colchicine for COVID-19
The World Health Organization (WHO) has advised against the use of the antidepressant drug fluvoxamine and the gout drug colchicine for patients with mild-to-moderate COVID-19.
A WHO expert panel said there is insufficient evidence that the two drugs improve outcomes in COVID patients and that the drugs may cause adverse reactions.
The panel based its advice on data from three clinical fluvoxamine trials and seven colchicine trials. Citing the lack of adequate data, the WHO did not make any recommendation on the use of the two drugs for patients with severe and critical cases of COVID-19.